Background: In line with treat to target principles, many patients with inflammatory arthritis receive multiple DMARDs which can pose issues with compliance and will ultimately affect efficacy of treatment. A recent study, investigating patient compliance whilst on DMARDs and biologic therapies indicated that approximately 40% of patients on multiple therapies did not purchase or ingest their DMARD medication. In addition a narrative review of the literature (2010) found medication adherence to DMARDs ranged from 30% to 107%. Adherence rates greater than 100% indicated that patients took more than the prescribed amount of medication. In order to investigate compliance with medication, we conducted an anonymous survey of patients attending outpatient appointments. Methods: Medication compliance was investigated using a medication survey. All rheumatology patients attending for follow-up appointments over a period of 2 weeks were invited to participate. The surveys assessed which DMARDs patients were prescribed and how many doses of each medication were missed each month. In addition we investigated the reasons for missing medication doses and suggestions for improving compliance. Results: The completed surveys (N ¼ 105) demonstrate that 20% of patients on DMARDs miss one or more medication doses each month. Of those questioned, 78% of patients are taking multiple medications. The most frequently missed medications were MTX and folic acid (8.8%), however these were also the most commonly prescribed drugs with 65% of participants taking them. The most frequently cited reason for missing medication doses was forgetfulness. Conclusion: This study does not support the results of previous studies. The results of this study show that only 20% of patients missed doses of their medications. Therefore, concerns about poor patient compliance should not be a barrier to the prescription of DMARDs. To improve compliance, rheumatology staff could ask patients whether they require pill boxes or blister packs to aid in remembering to take medications. They could also suggest to patients that they set daily reminders, particularly if they use a smart phone, in order to increase compliance. Pooled data from patients who received placebo during placebo-controlled study periods were also analysed.
Results: As of Sep 2012, 3595 patients (All-Exposure population) had received up to 20 courses of RTX over the 11-year observation period (14 816 pt-yrs). Of these patients, 1246 had >5 years follow-up. The placebo population comprised 818 patients (1107 pt-yrs) with a mean follow-up of 1-1.5 years. In the All-Exposure population, infusionrelated reaction (IRR) was the most frequent adverse event (AE); most were grade 1 or 2, were rarely serious (0.5%), and primarily occurred following the 1st infusion of the 1st course (799/3595 patients; 22%). Rates per 100 pt-yrs for AEs, serious AEs (SAEs), and infections were not increased when compared with placebo. The overall serious infection rate in RTX-treated patients was 3.76 events/100 pt-yrs (2.71 events/100 pt-yrs in patients treated for > 5 yrs) and was comparable to that observed in the placebo population (3.79 events/100 pt-yrs). Pneumonia was the most frequently reported serious infection (2% of RTX patients). There were no cases of hepatitis B reactivation. Serious opportunistic infections were rare (0.05/100 pt-yrs in RTX patients vs 0.09/100 pt-yrs in placebo). One confirmed case of PML in the RA clinical trial programme has been reported, as previously described in 2009. Following RTX treatment, low immunoglobulin (Ig) concentrations (particularly IgM, less often IgG) were observed. For both Ig classes, serious infection rates were similar before and during/after development of low Ig. No increased risk of malignancy over time or course was evident, and MI rates (0.39/100 pt-yrs) were consistent with rates in the general RA population (0.48-0.59/100 pt-yrs). Conclusion: These long-term data from 3595 patients treated with RTX over 11 years (14 816 pt-yrs) of follow-up in clinical trials confirm that RTX remains well tolerated over time and multiple courses, with a consistent safety profile. No new safety signals were observed with increasing duration of exposure. Apart from IRRs and low Ig (where there was a lack of placebo comparator), the overall safety profile of RTX remains similar to that for the pooled placebo population and is consistent with published data for moderate to severe RA and with previous analyses of this patient cohort. 
